Phase 2 N=97 Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Lymphoma
Primary: Overall Response Rate — 53.3; 76.1 percentage of participants — p=0.29
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=120 Biatain Ibu vs. Biatain in Painful Chronic Venous Leg Ulcers
Leg Ulcers
Primary: Pain Relief — 22; 31; 26; 31 percentage of scores within category — p=0.0438
Phase 2 N=85 Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
Chemotherapy-induced Nausea and Vomiting
Primary: Complete Response Rate for Delayed Chemotherapy Induced Nausea & Vomiting — 13 participants
Phase 2 N=26 Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
Ovarian Cancer
Primary: Occurrence of a DLT (Dose Limiting Toxicity) — 0; 1 Participants
Phase 2 N=45 Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Time to Disease Progression — 6.87 months
N/A N=118 Safety and Effectiveness Study of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes
Presbyopia
Primary: Improvement in Uncorrected Near Visual Acuity — 78.2 percentage of participants
Phase 2 N=71 Rosiglitazone Effect on Mitochondria and Lipoatrophy
HIV Infections
Primary: Change in Limb Fat at 48 Weeks — 448; 153 grams — p=0.02
Phase 2 N=57 A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
Gastroparesis
Primary: Dose-normalized Levodopa (L-DOPA) Area Under the Plasma Concentration-time Curve From Zero to 4 Hours AUC(0-4) at Baseline — 24.13; 24.81…
N/A N=21 Assessment of an Automatic Closed-loop Insulin Delivery System
Diabetes Mellitus, Type 1
Primary: Safety of Automatic Closed Loop Insulin Delivery System in Adolescents and Adults With Type 1 Diabetes — 9; 6; 0; 0 Events
Phase 3 N=892 Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Morning -Pre-dose Trough FEV1 Over 52 Weeks — 0.133; 0.076; 0.068; 0.107 Liters
Phase 2 N=35 Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Lymphoma
Primary: Dose Limiting Toxicity (DLT) for Phase I Patients — 0 patients
N/A N=21 The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble
Scleral Buckling
Primary: Complete Resolution of Intraocular Gas Bubble — 40.4; 37.8 Duration in days, gas bubble
N/A N=100 Airway Scope and Macintosh Laryngoscope for Tracheal Intubation in Patients Lying on the Ground
Intubation
Primary: Intubation Time — 18; 35 seconds
Phase 3 N=62 Montelukast for Early Life Wheezing
Lung Diseases · Asthma
Primary: Number of Wheezing-free Days of Infant (Observed by Primary Caregiver) — 25.5; 30.5 Days
N/A N=60 Arterial Stiffness in Type I Diabetes Mellitus
Arterial Stiffness in Youth With Type 1 Diabetes
Primary: Determine the Difference Between Acute Effect of a Mixed Meal on Radial Artery Stiffness in Subjects With Type I Diabetes Mellitus Who do and Who do Not Take an…